Abstract
Abstract BAFF and APRIL, crucial to B cell function, play a role in multiple sclerosis (MS), with therapeutic blockade linked to worsened disease. These cytokines signal through the receptors: BAFFR, TACI, and BCMA. BCMA stands out in MS due to elevated soluble levels in the cerebrospinal fluid. Our prior study using EAE revealed increased disease severity in BCMA knockout mice. Additionally, BCMA showed divergent roles in response to anti-CD20 and TACI-Fc treatments in EAE, enhancing anti-CD20 therapy responsiveness but diminishing TACI-Fc efficacy. The contrasting effects of BCMA on these treatments led us to explore its function in cell types beyond B cells. Here, we report that BCMA is highly expressed on microglial cells, and infiltrating Ly6C+ myeloid cells in the CNS of wildtype mice with EAE. Additionally, we found that BCMA-/- mice exhibited altered CD86 expression on microglial cells and elevated iNOS on infiltrating macrophages, suggesting a role in skewing towards an M1 phenotype in the CNS during EAE. In the lymph nodes, we also observed a similar effect on the M1-type macrophages in BCMA-/- mice compared to BCMA+/+ mice. These findings offer evidence of a novel role for BCMA in modulating microglia and macrophage function, providing additional insights into the intricate role that BAFF and APRIL play in neuroautoimmune diseases.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
